<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02641353</url>
  </required_header>
  <id_info>
    <org_study_id>CC-10004-CP-032</org_study_id>
    <secondary_id>20200157</secondary_id>
    <nct_id>NCT02641353</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Bioavailability of Apremilast Oral Suspension Relative to Tablet and to Assess Effect of Food on the Pharmacokinetics (PK) of the Oral Suspension</brief_title>
  <official_title>A Phase 1, Open-Label, Randomized Three-Period, Six-Sequence Crossover Study In Healthy Adult Subjects To Evaluate The Bioavailablity Of An Oral Suspension Formulation Relative To The Tablet Formulation Of Apremilast And To Assess The Effect Of Food On The Pharmacokinetics Of The Oral Suspension Formulation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess how much of apremilast is found in the blood unchanged&#xD;
      when administered as an oral suspension compared to when it is administered as a tablet&#xD;
      formulation. The effect of food on apremilast oral suspension will also be evaluated. In&#xD;
      addition, information on the safety and tolerability of apremilast will be obtained.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase 1, open-label, randomized, three-period, six-sequence crossover study in&#xD;
      healthy subjects. The study will consist of a screening phase, baseline (Day -1), three study&#xD;
      periods, and a follow-up phone call. Each study period will be four days in duration (Day 1&#xD;
      through Day 4) followed by a five-day washout between doses.&#xD;
&#xD;
      Eligible participants will be admitted into the study center on Day -1 of study Period 1 for&#xD;
      baseline measurements. During each study period, participants will receive a single 30 mg&#xD;
      oral dose of apremilast on Day 1 according to the assigned treatment sequence. Participants&#xD;
      will be confined at the study center from Day 1 of study Period 1 through Day 4 of study&#xD;
      Period 3, including the 5 day washout between doses. All participants will be discharged from&#xD;
      the study center on Day 4 of study Period 3 following completion of required study&#xD;
      procedures. A follow-up phone call will occur approximately four days after the discharge&#xD;
      from the study center.&#xD;
&#xD;
      The study will be conducted in compliance with International Conference on Harmonisation&#xD;
      (ICH) Good Clinical Practices (GCPs).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 5, 2016</start_date>
  <completion_date type="Actual">February 27, 2016</completion_date>
  <primary_completion_date type="Actual">February 27, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) of Apremilast</measure>
    <time_frame>Predose and at 0.5, 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48, 60 and 72 hours after dosing on day 1 of each treatment period.</time_frame>
    <description>Concentrations of apremilast in plasma were measured using a validated liquid chromatography tandem mass spectrometry assay.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Concentration-time Curve From Time Zero to the Last Measured Time Point (AUC0-t) for Apremilast</measure>
    <time_frame>Predose and at 0.5, 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48, 60 and 72 hours after dosing on day 1 of each treatment period.</time_frame>
    <description>Concentrations of apremilast in plasma were measured using a validated liquid chromatography tandem mass spectrometry assay. AUC from time zero to the last measured time point was calculated by the linear trapezoidal method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Concentration-time Curve From Time Zero to Infinity (AUC0-∞) for Apremilast</measure>
    <time_frame>Predose and at 0.5, 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48, 60 and 72 hours after dosing on day 1 of each treatment period.</time_frame>
    <description>Concentrations of apremilast in plasma were measured using a validated liquid chromatography tandem mass spectrometry assay. AUC from time zero to infinity was calculated as (AUC0-t + Ct/λz), where Ct is the last quantifiable concentration, and λz is the apparent terminal rate constant.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Maximum Observed Plasma Concentration (Tmax) of Apremilast</measure>
    <time_frame>Predose and at 0.5, 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48, 60 and 72 hours after dosing on day 1 of each treatment period.</time_frame>
    <description>Concentrations of apremilast in plasma were measured using a validated liquid chromatography tandem mass spectrometry assay.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal Elimination Half-life (T1/2) of Apremilast</measure>
    <time_frame>Predose and at 0.5, 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48, 60 and 72 hours after dosing on day 1 of each treatment period.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Clearance of Apremilast From Plasma After Extravascular Administration (CL/F)</measure>
    <time_frame>Predose and at 0.5, 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48, 60 and 72 hours after dosing on day 1 of each treatment period.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Volume of Distribution of Apremilast During the Terminal Phase (Vz/F)</measure>
    <time_frame>Predose and at 0.5, 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48, 60 and 72 hours after dosing on day 1 of each treatment period.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Lag Time (Tlag) of Apremilast</measure>
    <time_frame>Predose and at 0.5, 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48, 60 and 72 hours after dosing on day 1 of each treatment period.</time_frame>
    <description>Lag time is the delay between the time of administration and start of absorption.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Relative Bioavailability (F) of Apremilast Oral Suspension Formulation</measure>
    <time_frame>Predose and at 0.5, 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48, 60 and 72 hours after dosing on day 1 of each treatment period.</time_frame>
    <description>Relative bioavailability of the oral suspension formulation compared to the tablet formulation, calculated as (AUC0-∞/Dose[oral suspension]) / (AUC0-∞/Dose[tablet]) * 100%.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment-emergent Adverse Events</measure>
    <time_frame>From first dose of study drug in treatment period 1 to 8 days after the last dose; up to 18 days.</time_frame>
    <description>An adverse event (AE) is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a participant during the course of a study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the participant's health, including laboratory test values, regardless of etiology.&#xD;
A treatment-emergent AE (TEAE) was defined as any AE that occurred after dosing of the study drug.&#xD;
A serious adverse event (SAE) is any AE occurring at any dose that:&#xD;
Resulted in death;&#xD;
Was life-threatening;&#xD;
Required inpatient hospitalization or prolongation of existing hospitalization;&#xD;
Resulted in persistent or significant disability/incapacity;&#xD;
Was a congenital anomaly/birth defect;&#xD;
Constituted an important medical event.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Treatment A: Apremilast 30 mg Tablet - Fasted</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single oral dose of 30 mg apremilast tablet after an overnight fast.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B: Apremilast 30 mg Oral Suspension - Fasted</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single oral dose of 30 mg apremilast oral suspension formulation (6 mL) after an overnight fast.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment C - Apremilast 30 mg Oral Suspension - Fed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single oral dose of 30 mg apremilast oral suspension formulation (6 mL) after a high-fat meal.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apremilast Tablet</intervention_name>
    <description>30 mg tablet</description>
    <arm_group_label>Treatment A: Apremilast 30 mg Tablet - Fasted</arm_group_label>
    <other_name>Otzela</other_name>
    <other_name>CC-10004</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apremilast Oral Suspension</intervention_name>
    <description>30 mg oral suspension</description>
    <arm_group_label>Treatment B: Apremilast 30 mg Oral Suspension - Fasted</arm_group_label>
    <arm_group_label>Treatment C - Apremilast 30 mg Oral Suspension - Fed</arm_group_label>
    <other_name>Otzela</other_name>
    <other_name>CC-10004</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Subjects must satisfy ALL of the following criteria to be eligible for enrollment into the&#xD;
        study:&#xD;
&#xD;
          1. Must understand and voluntarily sign a written Informed Consent (ICF) prior to any&#xD;
             study-related procedures being performed.&#xD;
&#xD;
          2. Must be able to communicate with the investigator, understand and comply with the&#xD;
             requirements of the study, and agree to adhere to restrictions and examination&#xD;
             schedules.&#xD;
&#xD;
          3. Male and female subjects of any race between 18 to 55 years of age (inclusive), and in&#xD;
             good health as determined by the Investigator at the time of signing the informed&#xD;
             consent document.&#xD;
&#xD;
          4. Have a Body Mass Index (BMI) between 18 and 33 kg/m^2 (inclusive).&#xD;
&#xD;
          5. No clinically significant laboratory test results as determined by the investigator.&#xD;
&#xD;
          6. At the screening visit, must be afebrile, with supine systolic blood pressure (BP): 90&#xD;
             to 140 mmHg, supine diastolic BP: 50 to 90 mmHg, and pulse rate: 40 to 110 bpm.&#xD;
             Eligibility criteria for vital signs performed during check-in and/or predose on Day 1&#xD;
             will be at the discretion of the Investigator.&#xD;
&#xD;
          7. Must have a normal or clinically acceptable 12-lead electrocardiogram (ECG). Subjects&#xD;
             must have a QTcF value ≤ 450 msec.&#xD;
&#xD;
          8. Contraception Requirements:&#xD;
&#xD;
               -  Must comply with the following acceptable forms of contraception. All female of&#xD;
                  childbearing potential (FCBP) must use one of the approved contraceptive options&#xD;
                  as described below while taking apremilast and for at least 28 days after&#xD;
                  administration of the last dose of the apremilast.&#xD;
&#xD;
               -  At the time of study entry, and at any time during the study when a FCBP's&#xD;
                  contraceptive measures or ability to become pregnant changes, the Investigator&#xD;
                  will educate the subject regarding contraception options and the correct and&#xD;
                  consistent use of effective contraceptive methods in order to successfully&#xD;
                  prevent pregnancy&#xD;
&#xD;
             All FCBP must have a negative pregnancy test at Visits 1 and 2. All FCBP subjects who&#xD;
             engage in activity in which conception is possible must use one of the approved&#xD;
             contraceptive options described below:&#xD;
&#xD;
             Option 1: Any one of the following highly effective methods: hormonal contraception&#xD;
             (oral, injection, implant, transdermal patch, vaginal ring); intrauterine device&#xD;
             (IUD); tubal ligation; or partner's vasectomy; OR Option 2: Male or female condom&#xD;
             (latex condom or non-latex condom NOT made out of natural [animal] membrane [for&#xD;
             example, polyurethane]); PLUS one of the following additional barrier methods: (a)&#xD;
             diaphragm with spermicide; (b) cervical cap with spermicide; or (c) contraceptive&#xD;
             sponge with spermicide.&#xD;
&#xD;
             Male subjects (including those who have had a vasectomy) who engage in activity in&#xD;
             which conception is possible must use barrier contraception (latex or non-latex&#xD;
             condoms NOT made out of natural [animal] membrane [for example, polyurethane]) while&#xD;
             on investigational product (IP) and for at least 28 days after the last dose of IP.&#xD;
&#xD;
          9. Must agree to refrain from donating sperm, blood or plasma (other than for this study)&#xD;
             while participating in this study and for at least 28 days after the last dose of&#xD;
             investigational product.&#xD;
&#xD;
         10. Subject is willing and able to adhere to the study visit schedule and other protocol&#xD;
             requirements&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        The presence of ANY of the following will exclude any healthy subject from enrollment into&#xD;
        the study:&#xD;
&#xD;
          1. History of any clinically significant and relevant neurological, psychiatric,&#xD;
             gastrointestinal, renal, hepatic, cardiovascular, psychological, pulmonary, metabolic,&#xD;
             endocrine, hematological, allergic disease, drug allergies, or other major disorders.&#xD;
&#xD;
          2. Any condition which places the subject at unacceptable risk if he were to participate&#xD;
             in the study, or confounds the ability to interpret data from the study.&#xD;
&#xD;
          3. Use of any prescribed systemic or topical medication within 30 days of the first dose&#xD;
             administration.&#xD;
&#xD;
          4. Use of any non-prescribed systemic or topical medication (including vitamin/mineral&#xD;
             supplements, and herbal medicines) within 14 days of the first dose administration,&#xD;
             Any surgical or medical condition possibly affecting drug absorption, distribution,&#xD;
             metabolism and excretion, eg, bariatric procedure, colon resection, irritable bowel&#xD;
             syndrome, Crohn's disease, etc. Subjects with cholecystectomy and appendectomy may be&#xD;
             included.&#xD;
&#xD;
          5. Exposure to an investigational drug (new chemical entity) within 30 days prior to the&#xD;
             first dose administration or 5 half-lives of that investigational drug, if known&#xD;
             (whichever is longer).&#xD;
&#xD;
          6. Donated blood or plasma within 8 weeks before the first dose administration to a blood&#xD;
             bank or blood donation center.&#xD;
&#xD;
          7. History of drug abuse (as defined by the current version of the Diagnostic and&#xD;
             Statistical Manual [DSM]) within 2 years before dosing, or a positive drug screen&#xD;
             reflecting consumption of illicit drugs.&#xD;
&#xD;
          8. History of alcohol abuse (as defined by the current version of the DSM) within 2 years&#xD;
             before dosing, or a positive alcohol screen.&#xD;
&#xD;
          9. Known to have hepatitis, or known to be a carrier of the hepatitis B surface antigen&#xD;
             (HBsAg), or hepatitis C antibody (HCV Ab), or have a positive result to the test for&#xD;
             HBsAg, HCV Ab, or human immunodeficiency virus (HIV) antibodies at Screening.&#xD;
&#xD;
             -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Covance Clinical Research Unit Inc</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>December 23, 2015</study_first_submitted>
  <study_first_submitted_qc>December 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 29, 2015</study_first_posted>
  <results_first_submitted>June 1, 2021</results_first_submitted>
  <results_first_submitted_qc>July 14, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">August 5, 2021</results_first_posted>
  <last_update_submitted>July 14, 2021</last_update_submitted>
  <last_update_submitted_qc>July 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Apremilast</keyword>
  <keyword>Healthy volunteers</keyword>
  <keyword>Bioavailability</keyword>
  <keyword>Food effect</keyword>
  <keyword>Pharmacokinetic</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>Apremilast</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.</ipd_time_frame>
    <ipd_access_criteria>Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.</ipd_access_criteria>
    <ipd_url>http://www.amgen.com/datasharing</ipd_url>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled at a single site in the United States. The study consisted of three treatment periods separated by a 5-day washout period.</recruitment_details>
      <pre_assignment_details>Participants were randomly assigned to one of six treatment sequences. On day 1 of each treatment sequence participants received one of the following according to their assigned treatment sequence:&#xD;
Treatment A: Single oral dose of 30 mg apremilast tablet under fasted conditions&#xD;
Treatment B: Single oral dose of 30 mg apremilast oral suspension formulation under fasted conditions&#xD;
Treatment C: Single oral dose of 30 mg apremilast oral suspension formulation under fed conditions</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Sequence 1: Treatments ACB</title>
          <description>Participants received 30 mg apremilast oral tablet after an overnight fast on day 1 of treatment period 1, 30 mg apremilast oral suspension after a high-fat meal on day 1 of treatment period 2, and 30 mg apremilast oral suspension after an overnight fast on day 1 of treatment period 3.</description>
        </group>
        <group group_id="P2">
          <title>Sequence 2: Treatments CBA</title>
          <description>Participants received 30 mg apremilast oral suspension after a high-fat meal on day 1 of treatment period 1, 30 mg apremilast oral suspension after an overnight fast on day 1 of treatment period 2, and 30 mg apremilast oral tablet after an overnight fast on day 1 of treatment period 3.</description>
        </group>
        <group group_id="P3">
          <title>Sequence 3: Treatments BAC</title>
          <description>Participants received 30 mg apremilast oral suspension after an overnight fast on day 1 of treatment period 1, 30 mg apremilast oral tablet after an overnight fast on day 1 of treatment period 2, and 30 mg apremilast oral suspension after a high-fat meal on day 1 of treatment period 3.</description>
        </group>
        <group group_id="P4">
          <title>Sequence 4: Treatments ABC</title>
          <description>Participants received 30 mg apremilast oral tablet after an overnight fast on day 1 of treatment period 1, 30 mg apremilast oral suspension after an overnight fast on day 1 of treatment period 2, and 30 mg apremilast oral suspension after a high-fat meal on day 1 of treatment period 3.</description>
        </group>
        <group group_id="P5">
          <title>Sequence 5: Treatments CAB</title>
          <description>Participants received 30 mg apremilast oral suspension after a high-fat meal on day 1 of treatment period 1, 30 mg apremilast oral tablet after an overnight fast on day 1 of treatment period 2, and 30 mg apremilast oral suspension after an overnight fast on day 1 of treatment period 3.</description>
        </group>
        <group group_id="P6">
          <title>Sequence 6: Treatments BCA</title>
          <description>Participants received 30 mg apremilast oral suspension after an overnight fast on day 1 of treatment period 1, 30 mg apremilast oral suspension after a high-fat meal on day 1 of treatment period 2, and 30 mg apremilast oral tablet after an overnight fast on day 1 of treatment period 3.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All randomized participants</population>
      <group_list>
        <group group_id="B1">
          <title>Total</title>
          <description>Participants received a single dose of the following three treatments in one of six treatment sequences:&#xD;
Treatment A: Single oral dose of 30 mg apremilast tablet under fasted conditions&#xD;
Treatment B: Single oral dose of 30 mg apremilast oral suspension formulation under fasted conditions&#xD;
Treatment C: Single oral dose of 30 mg apremilast oral suspension formulation under fed conditions</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="34"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.3" lower_limit="19" upper_limit="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum Observed Plasma Concentration (Cmax) of Apremilast</title>
        <description>Concentrations of apremilast in plasma were measured using a validated liquid chromatography tandem mass spectrometry assay.</description>
        <time_frame>Predose and at 0.5, 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48, 60 and 72 hours after dosing on day 1 of each treatment period.</time_frame>
        <population>The pharmacokinetic (PK) population included all participants who received at least one dose of apremilast and had at least one measurable concentration datum.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A: Apremilast 30 mg Tablet - Fasted</title>
            <description>A single oral dose of 30 mg apremilast tablet after an overnight fast.</description>
          </group>
          <group group_id="O2">
            <title>Treatment B: Apremilast 30 mg Oral Suspension - Fasted</title>
            <description>A single oral dose of 30 mg apremilast oral suspension formulation (6 mL) after an overnight fast.</description>
          </group>
          <group group_id="O3">
            <title>Treatment C: Apremilast 30 mg Oral Suspension - Fed</title>
            <description>A single oral dose of 30 mg apremilast oral suspension formulation (6 mL) after a high-fat meal.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Plasma Concentration (Cmax) of Apremilast</title>
          <description>Concentrations of apremilast in plasma were measured using a validated liquid chromatography tandem mass spectrometry assay.</description>
          <population>The pharmacokinetic (PK) population included all participants who received at least one dose of apremilast and had at least one measurable concentration datum.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="323" spread="34.5"/>
                    <measurement group_id="O2" value="274" spread="32.2"/>
                    <measurement group_id="O3" value="215" spread="33.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>To assess the bioavailability between the apremilast oral suspension and tablet formulation an analysis of variance (ANOVA) model, with treatment, sequence, and period as fixed effects and subject nested within sequence as a random effect, was performed on the natural log-transformed Cmax.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>84.9</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>77.3</ci_lower_limit>
            <ci_upper_limit>93.2</ci_upper_limit>
            <estimate_desc>Ratio of adjusted geometric means (Treatment B / Treatment A) expressed as a percentage.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>To assess the effect of food on the PK of apremilast oral suspension formulation, an ANOVA model, with treatment, sequence, and period as fixed effects and subject nested within sequence as a random effect, was performed on the natural log-transformed Cmax.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>78.2</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>71.2</ci_lower_limit>
            <ci_upper_limit>86.0</ci_upper_limit>
            <estimate_desc>Ratio of adjusted geometric means (Treatment C / Treatment B) expressed as a percentage.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Concentration-time Curve From Time Zero to the Last Measured Time Point (AUC0-t) for Apremilast</title>
        <description>Concentrations of apremilast in plasma were measured using a validated liquid chromatography tandem mass spectrometry assay. AUC from time zero to the last measured time point was calculated by the linear trapezoidal method.</description>
        <time_frame>Predose and at 0.5, 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48, 60 and 72 hours after dosing on day 1 of each treatment period.</time_frame>
        <population>The pharmacokinetic population</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A: Apremilast 30 mg Tablet - Fasted</title>
            <description>A single oral dose of 30 mg apremilast tablet after an overnight fast.</description>
          </group>
          <group group_id="O2">
            <title>Treatment B: Apremilast 30 mg Oral Suspension - Fasted</title>
            <description>A single oral dose of 30 mg apremilast oral suspension formulation (6 mL) after an overnight fast.</description>
          </group>
          <group group_id="O3">
            <title>Treatment C: Apremilast 30 mg Oral Suspension - Fed</title>
            <description>A single oral dose of 30 mg apremilast oral suspension formulation (6 mL) after a high-fat meal.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-time Curve From Time Zero to the Last Measured Time Point (AUC0-t) for Apremilast</title>
          <description>Concentrations of apremilast in plasma were measured using a validated liquid chromatography tandem mass spectrometry assay. AUC from time zero to the last measured time point was calculated by the linear trapezoidal method.</description>
          <population>The pharmacokinetic population</population>
          <units>ng*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3130" spread="38.9"/>
                    <measurement group_id="O2" value="2740" spread="43.1"/>
                    <measurement group_id="O3" value="3160" spread="41.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>To assess the bioavailability between the apremilast oral suspension and tablet formulation an ANOVA model, with treatment, sequence, and period as fixed effects and subject nested within sequence as a random effect, was performed on the natural log-transformed AUC0-t.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>87.6</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>83.0</ci_lower_limit>
            <ci_upper_limit>92.5</ci_upper_limit>
            <estimate_desc>Ratio of adjusted geometric means (Treatment B / Treatment A) expressed as a percentage.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>To assess the effect of food on the PK of apremilast oral suspension formulation, an ANOVA model, with treatment, sequence, and period as fixed effects and subject nested within sequence as a random effect, was performed on the natural log-transformed AUC0-t.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>115.3</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>109.2</ci_lower_limit>
            <ci_upper_limit>121.7</ci_upper_limit>
            <estimate_desc>Ratio of adjusted geometric means (Treatment C / Treatment B) expressed as a percentage.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Concentration-time Curve From Time Zero to Infinity (AUC0-∞) for Apremilast</title>
        <description>Concentrations of apremilast in plasma were measured using a validated liquid chromatography tandem mass spectrometry assay. AUC from time zero to infinity was calculated as (AUC0-t + Ct/λz), where Ct is the last quantifiable concentration, and λz is the apparent terminal rate constant.</description>
        <time_frame>Predose and at 0.5, 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48, 60 and 72 hours after dosing on day 1 of each treatment period.</time_frame>
        <population>The pharmacokinetic population</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A: Apremilast 30 mg Tablet - Fasted</title>
            <description>A single oral dose of 30 mg apremilast tablet after an overnight fast.</description>
          </group>
          <group group_id="O2">
            <title>Treatment B: Apremilast 30 mg Oral Suspension - Fasted</title>
            <description>A single oral dose of 30 mg apremilast oral suspension formulation (6 mL) after an overnight fast.</description>
          </group>
          <group group_id="O3">
            <title>Treatment C: Apremilast 30 mg Oral Suspension - Fed</title>
            <description>A single oral dose of 30 mg apremilast oral suspension formulation (6 mL) after a high-fat meal.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-time Curve From Time Zero to Infinity (AUC0-∞) for Apremilast</title>
          <description>Concentrations of apremilast in plasma were measured using a validated liquid chromatography tandem mass spectrometry assay. AUC from time zero to infinity was calculated as (AUC0-t + Ct/λz), where Ct is the last quantifiable concentration, and λz is the apparent terminal rate constant.</description>
          <population>The pharmacokinetic population</population>
          <units>ng*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3160" spread="38.7"/>
                    <measurement group_id="O2" value="2760" spread="43.2"/>
                    <measurement group_id="O3" value="3190" spread="41.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>To assess the bioavailability between the apremilast oral suspension and tablet formulation an ANOVA model, with treatment, sequence, and period as fixed effects and subject nested within sequence as a random effect, was performed on the natural log-transformed AUC0-∞.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>87.8</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>83.2</ci_lower_limit>
            <ci_upper_limit>92.6</ci_upper_limit>
            <estimate_desc>Ratio of adjusted geometric means (Treatment B / Treatment A) expressed as a percentage.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>To assess the effect of food on the PK of apremilast oral suspension formulation, an ANOVA model, with treatment, sequence, and period as fixed effects and subject nested within sequence as a random effect, was performed on the natural log-transformed AUC0-∞.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>115.0</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>109.0</ci_lower_limit>
            <ci_upper_limit>121.7</ci_upper_limit>
            <estimate_desc>Ratio of adjusted geometric means (Treatment C / Treatment B) expressed as a percentage.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Maximum Observed Plasma Concentration (Tmax) of Apremilast</title>
        <description>Concentrations of apremilast in plasma were measured using a validated liquid chromatography tandem mass spectrometry assay.</description>
        <time_frame>Predose and at 0.5, 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48, 60 and 72 hours after dosing on day 1 of each treatment period.</time_frame>
        <population>The PK population</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A: Apremilast 30 mg Tablet - Fasted</title>
            <description>A single oral dose of 30 mg apremilast tablet after an overnight fast.</description>
          </group>
          <group group_id="O2">
            <title>Treatment B: Apremilast 30 mg Oral Suspension - Fasted</title>
            <description>A single oral dose of 30 mg apremilast oral suspension formulation (6 mL) after an overnight fast.</description>
          </group>
          <group group_id="O3">
            <title>Treatment C: Apremilast 30 mg Oral Suspension - Fed</title>
            <description>A single oral dose of 30 mg apremilast oral suspension formulation (6 mL) after a high-fat meal.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Maximum Observed Plasma Concentration (Tmax) of Apremilast</title>
          <description>Concentrations of apremilast in plasma were measured using a validated liquid chromatography tandem mass spectrometry assay.</description>
          <population>The PK population</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.00" lower_limit="1.00" upper_limit="5.00"/>
                    <measurement group_id="O2" value="2.00" lower_limit="1.50" upper_limit="5.00"/>
                    <measurement group_id="O3" value="5.00" lower_limit="1.50" upper_limit="12.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Tmax was analyzed by nonparametric methods. The median difference and 90% confidence interval (CI) of the median difference were calculated from the Hodges-Lehrmann estimate.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.1508</p_value>
            <method>Wilcoxon signed-rank test</method>
            <param_type>Median Difference</param_type>
            <param_value>0.25</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.00</ci_lower_limit>
            <ci_upper_limit>0.50</ci_upper_limit>
            <estimate_desc>Median difference (Treatment B - Treatment A) calculated from the Hodges-Lehmann estimate</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Tmax was analyzed by nonparametric methods. The median difference and 90% CI of the median difference were calculated from the Hodges-Lehrmann estimate.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Wilcoxon signed-rank test</method>
            <param_type>Median Difference</param_type>
            <param_value>2.25</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.27</ci_lower_limit>
            <ci_upper_limit>3.25</ci_upper_limit>
            <estimate_desc>Median difference (Treatment C - Treatment B) calculated from the Hodges-Lehmann estimate</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Terminal Elimination Half-life (T1/2) of Apremilast</title>
        <time_frame>Predose and at 0.5, 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48, 60 and 72 hours after dosing on day 1 of each treatment period.</time_frame>
        <population>PK population</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A: Apremilast 30 mg Tablet - Fasted</title>
            <description>A single oral dose of 30 mg apremilast tablet after an overnight fast.</description>
          </group>
          <group group_id="O2">
            <title>Treatment B: Apremilast 30 mg Oral Suspension - Fasted</title>
            <description>A single oral dose of 30 mg apremilast oral suspension formulation (6 mL) after an overnight fast.</description>
          </group>
          <group group_id="O3">
            <title>Treatment C: Apremilast 30 mg Oral Suspension - Fed</title>
            <description>A single oral dose of 30 mg apremilast oral suspension formulation (6 mL) after a high-fat meal.</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Elimination Half-life (T1/2) of Apremilast</title>
          <population>PK population</population>
          <units>hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.89" spread="34.5"/>
                    <measurement group_id="O2" value="8.51" spread="31.8"/>
                    <measurement group_id="O3" value="7.54" spread="30.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Apparent Clearance of Apremilast From Plasma After Extravascular Administration (CL/F)</title>
        <time_frame>Predose and at 0.5, 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48, 60 and 72 hours after dosing on day 1 of each treatment period.</time_frame>
        <population>PK population</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A: Apremilast 30 mg Tablet - Fasted</title>
            <description>A single oral dose of 30 mg apremilast tablet after an overnight fast.</description>
          </group>
          <group group_id="O2">
            <title>Treatment B: Apremilast 30 mg Oral Suspension - Fasted</title>
            <description>A single oral dose of 30 mg apremilast oral suspension formulation (6 mL) after an overnight fast.</description>
          </group>
          <group group_id="O3">
            <title>Treatment C: Apremilast 30 mg Oral Suspension - Fed</title>
            <description>A single oral dose of 30 mg apremilast oral suspension formulation (6 mL) after a high-fat meal.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Clearance of Apremilast From Plasma After Extravascular Administration (CL/F)</title>
          <population>PK population</population>
          <units>L/h</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.51" spread="38.7"/>
                    <measurement group_id="O2" value="10.9" spread="43.2"/>
                    <measurement group_id="O3" value="9.42" spread="41.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Apparent Volume of Distribution of Apremilast During the Terminal Phase (Vz/F)</title>
        <time_frame>Predose and at 0.5, 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48, 60 and 72 hours after dosing on day 1 of each treatment period.</time_frame>
        <population>PK population</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A: Apremilast 30 mg Tablet - Fasted</title>
            <description>A single oral dose of 30 mg apremilast tablet after an overnight fast.</description>
          </group>
          <group group_id="O2">
            <title>Treatment B: Apremilast 30 mg Oral Suspension - Fasted</title>
            <description>A single oral dose of 30 mg apremilast oral suspension formulation (6 mL) after an overnight fast.</description>
          </group>
          <group group_id="O3">
            <title>Treatment C: Apremilast 30 mg Oral Suspension - Fed</title>
            <description>A single oral dose of 30 mg apremilast oral suspension formulation (6 mL) after a high-fat meal.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Volume of Distribution of Apremilast During the Terminal Phase (Vz/F)</title>
          <population>PK population</population>
          <units>L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="108" spread="45.2"/>
                    <measurement group_id="O2" value="133" spread="43.7"/>
                    <measurement group_id="O3" value="102" spread="38.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Lag Time (Tlag) of Apremilast</title>
        <description>Lag time is the delay between the time of administration and start of absorption.</description>
        <time_frame>Predose and at 0.5, 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48, 60 and 72 hours after dosing on day 1 of each treatment period.</time_frame>
        <population>PK population</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A: Apremilast 30 mg Tablet - Fasted</title>
            <description>A single oral dose of 30 mg apremilast tablet after an overnight fast.</description>
          </group>
          <group group_id="O2">
            <title>Treatment B: Apremilast 30 mg Oral Suspension - Fasted</title>
            <description>A single oral dose of 30 mg apremilast oral suspension formulation (6 mL) after an overnight fast.</description>
          </group>
          <group group_id="O3">
            <title>Treatment C: Apremilast 30 mg Oral Suspension - Fed</title>
            <description>A single oral dose of 30 mg apremilast oral suspension formulation (6 mL) after a high-fat meal.</description>
          </group>
        </group_list>
        <measure>
          <title>Lag Time (Tlag) of Apremilast</title>
          <description>Lag time is the delay between the time of administration and start of absorption.</description>
          <population>PK population</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O2" value="0.00" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O3" value="0.00" lower_limit="0.00" upper_limit="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Relative Bioavailability (F) of Apremilast Oral Suspension Formulation</title>
        <description>Relative bioavailability of the oral suspension formulation compared to the tablet formulation, calculated as (AUC0-∞/Dose[oral suspension]) / (AUC0-∞/Dose[tablet]) * 100%.</description>
        <time_frame>Predose and at 0.5, 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48, 60 and 72 hours after dosing on day 1 of each treatment period.</time_frame>
        <population>PK population. Relative bioavailability calculated for each of the oral suspension treatments as pre-specified in the Protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment B: Apremilast 30 mg Oral Suspension - Fasted</title>
            <description>A single oral dose of 30 mg apremilast oral suspension formulation (6 mL) after an overnight fast.</description>
          </group>
          <group group_id="O2">
            <title>Treatment C: Apremilast 30 mg Oral Suspension - Fed</title>
            <description>A single oral dose of 30 mg apremilast oral suspension formulation (6 mL) after a high-fat meal.</description>
          </group>
        </group_list>
        <measure>
          <title>Relative Bioavailability (F) of Apremilast Oral Suspension Formulation</title>
          <description>Relative bioavailability of the oral suspension formulation compared to the tablet formulation, calculated as (AUC0-∞/Dose[oral suspension]) / (AUC0-∞/Dose[tablet]) * 100%.</description>
          <population>PK population. Relative bioavailability calculated for each of the oral suspension treatments as pre-specified in the Protocol.</population>
          <units>percent availability</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.6" spread="16.1"/>
                    <measurement group_id="O2" value="101" spread="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Treatment-emergent Adverse Events</title>
        <description>An adverse event (AE) is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a participant during the course of a study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the participant's health, including laboratory test values, regardless of etiology.&#xD;
A treatment-emergent AE (TEAE) was defined as any AE that occurred after dosing of the study drug.&#xD;
A serious adverse event (SAE) is any AE occurring at any dose that:&#xD;
Resulted in death;&#xD;
Was life-threatening;&#xD;
Required inpatient hospitalization or prolongation of existing hospitalization;&#xD;
Resulted in persistent or significant disability/incapacity;&#xD;
Was a congenital anomaly/birth defect;&#xD;
Constituted an important medical event.</description>
        <time_frame>From first dose of study drug in treatment period 1 to 8 days after the last dose; up to 18 days.</time_frame>
        <population>The safety population included all participants who received at least one dose of apremilast.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A: Apremilast 30 mg Tablet - Fasted</title>
            <description>A single oral dose of 30 mg apremilast tablet after an overnight fast.</description>
          </group>
          <group group_id="O2">
            <title>Treatment B: Apremilast 30 mg Oral Suspension - Fasted</title>
            <description>A single oral dose of 30 mg apremilast oral suspension formulation (6 mL) after an overnight fast.</description>
          </group>
          <group group_id="O3">
            <title>Treatment C: Apremilast 30 mg Oral Suspension - Fed</title>
            <description>A single oral dose of 30 mg apremilast oral suspension formulation (6 mL) after a high-fat meal.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-emergent Adverse Events</title>
          <description>An adverse event (AE) is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a participant during the course of a study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the participant's health, including laboratory test values, regardless of etiology.&#xD;
A treatment-emergent AE (TEAE) was defined as any AE that occurred after dosing of the study drug.&#xD;
A serious adverse event (SAE) is any AE occurring at any dose that:&#xD;
Resulted in death;&#xD;
Was life-threatening;&#xD;
Required inpatient hospitalization or prolongation of existing hospitalization;&#xD;
Resulted in persistent or significant disability/incapacity;&#xD;
Was a congenital anomaly/birth defect;&#xD;
Constituted an important medical event.</description>
          <population>The safety population included all participants who received at least one dose of apremilast.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any treatment-emergent adverse event (TEAE)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAEs related to study drug</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAEs leading to discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAEs leading to death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From first dose of study drug in treatment period 1 to 8 days after the last dose; up to 18 days.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Treatment A: Apremilast 30 mg Tablet - Fasted</title>
          <description>A single oral dose of 30 mg apremilast tablet after an overnight fast.</description>
        </group>
        <group group_id="E2">
          <title>Treatment B: Apremilast 30 mg Oral Suspension - Fasted</title>
          <description>A single oral dose of 30 mg apremilast oral suspension formulation (6 mL) after an overnight fast.</description>
        </group>
        <group group_id="E3">
          <title>Treatment C: Apremilast 30 mg Oral Suspension - Fed</title>
          <description>A single oral dose of 30 mg apremilast oral suspension formulation (6 mL) after a high-fat meal.</description>
        </group>
        <group group_id="E4">
          <title>Total</title>
          <description>Participants received a single dose of the following three treatments in one of six treatment sequences:&#xD;
Treatment A: Single oral dose of 30 mg apremilast tablet under fasted conditions&#xD;
Treatment B: Single oral dose of 30 mg apremilast oral suspension formulation under fasted conditions&#xD;
Treatment C: Single oral dose of 30 mg apremilast oral suspension formulation under fed conditions</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 18.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Feeling hot</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Amgen Inc.</organization>
      <phone>866-572-6436</phone>
      <email>medinfo@amgen.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

